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The relationship between prolactin (PRL) and the immune system has been demonstrated in the last two decades and has opened
new windows in the ﬁeld of immunoendocrinology. However, there are scarce reports about PRL in primary antiphospholipid
syndrome (pAPS). The objective of this study was to evaluate PRL levels in patients with pAPS compared to healthy controls
and to investigate their possible clinical associations. Fifty-ﬁve pAPS patients according to Sapporo criteria were age- and sex-
matched with 41 healthy subjects. Individuals with secondary causes of hyperprolactinemia (HPRL) were excluded; demographic,
biometric,andclinicaldata,PRLlevels,antiphospholipidantibodies,inﬂammatorymarkers,andotherroutinelaboratoryﬁndings
were analyzed. PRL levels were similar between pAPS and healthy controls (8.94 ±7.02 versus 8.71 ±6.73ng/mL, P = .876). Nine
percent ofthepAPSpatientsand12.1%ofthecontrolsubjects presentedHPRL(P = .740).Comparisonbetween thepAPSpatients
with hyper- and normoprolactinemia revealed no signiﬁcant diﬀerences related to anthropometrics, clinical manifestations,
medications, smoking, and antiphospholipid antibodies (P>. 05). This study showed that HPRL does not seem to play a role
in clinical manifestations of the pAPS, diﬀerently from other autoimmune rheumatic diseases.
1.Introduction
Prolactin (PRL) is a peptide hormone secreted from the
anterior pituitary gland and regulated by tonic inhibition
of the hypothalamus via dopamine [1]. It is secreted not
only by the anterior pituitary gland, but also by many
extrapituitary sites, including immune cells [2]. Pituitary
secretion of PRL is stimulated by suckling and stress [2].
The relationship between PRL and the immune system has
been demonstrated in the last two decades and has opened
new windows in the ﬁeld of immunoendocrinology [2].
PRL has multiple immunostimulatory eﬀects and promotes
autoimmunity. It increases the synthesis of IFN-gamma and
IL-2 by Th1 lymphocytes [3]. Moreover, PRL activates Th2
lymphocytes with autoantibody production [3]a n di th a sa
role in reproduction, calcium metabolism, osmoregulation,
and behavior [4].
Hyperprolactinemia (HPRL) has been described in both
non-organ-speciﬁc autoimmune diseases such as systemic
lupus erythematosus (SLE), rheumatoid arthritis, systemic
sclerosis, and psoriatic arthritis, as well as organ-speciﬁc
autoimmune diseases such as celiac disease, type 1 diabetes
mellitus, Addison’s disease, and autoimmune thyroid dis-
eases [2]. However, there are scarce reports in the literature
regarding the signiﬁcance of PRL in antiphospholipid syn-
drome (APS). Recently, a study evaluated the clinical signif-
icance of HPRL in APS and concluded that PRL indirectly
may play a role in the pathogenesis of APS [5].
T h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t et h ep r e v a -
lence and clinical signiﬁcance of PRL levels in pAPS patients
and to compare them with healthy controls.
2.Methods
2.1. Patients. This comparative, descriptive, case-control
study was conducted at the Rheumatology Division of
the Hospital das Clinicas da Faculdade de Medicina da
Universidade de Sao Paulo.2 Clinical and Developmental Immunology
All patients fulﬁlled the 1997 revised Sapporo criteria
for the diagnosis of APS [6]. Anthropometric data, clinical
manifestations, and laboratory results from 55pAPS patients
were collected from the patients’ medical charts and com-
pared with sex-matched healthy controls. Exclusion criteria
were presence of other autoimmune diseases, such as SLE,
use of drugs that are known to aﬀect levels of PRL (i.e.,
psychotropic drugs, thyroid hormones, glucocorticoids, and
estrogens or contraceptives), and patients with secondary
causes of HPRL, such as primary hypothyroidism, end-stage
renal disease, or prolactinomas.
Comparative analyses were carried out between sex,
age, and disease duration. Anthropometric measurements
including weight (kg), height (cm), and body mass index
(weight/height2) were also performed. The following clinical
parameterswere evaluated:venousthrombosis (documented
deep vein thrombosis and/or pulmonary embolism), arterial
thrombosis (at least one of the following: documented
peripheral arterial thrombosis, stroke, transient ischemic
attacks, or acute myocardial infarction), livedo reticularis,
thrombocytopenia, recurrent spontaneous abortions, and in
utero fetal loss. In addition to the laboratory assessment of
serum PRL, all sera of the patients were screened also for
anticardiolipin antibodies, lupus anticoagulant, C-reactive
protein (CRP), and erythrocyte sedimentation rate (ESR).
2.2. Antiphospholipid Antibodies. IgG and IgM anticardi-
olipin antibodies (ACLs) were estimated at least twice
using an enzyme-linked immunosorbent assay (ELISA) as
previously described [7]. There was an interval of 12 weeks
between each measurement. Brieﬂy, 50μL of cardiolipin
(Sigma,StLouis,MO,USA)dissolved at50μg/mLin ethanol
was used to sensitize polystyrene microtiter plates that were
left to dry overnight at 4◦C. Nonspeciﬁc binding sites were
blocked using 30% heat-inactivated fetal calf serum in PBS
(FCS/PBS) for one hour. Fifty microliters of each serum
sample diluted 1:50 in FCS/PBS was added in duplicate
to the plates, followed by alkaline phosphatase-conjugated
goat antihuman IgG (Sigma, St Louis, MO, USA). The
manufacturer’s cutoﬀ values were used. For the diagnosis of
the syndrome, values above 20GPL or MPL were considered
positive according to the criteria established by Sapporo [6].
Lupus anticoagulant was measured according to interna-
tional guidelines using activated partial thromboplastin time
(APTT-DiagnosticaStago,France)anddilutedRussell’sviper
venom time (dRVVT-Trinity Biotech, Wiclow, Ireland) [8].
2.3. Inﬂammatory Markers. CRP was detected by nephelom-
etry and ESR by modiﬁed Westergreen.
2.4. PRL Measurement. They were measured by ﬂuoroim-
munometric assay (AutoDELFIA Prolactin, PerkinElmer Life
analyticScience,Turku,Finland). Referencevaluesforwomen
are 2.0 to 15.0ng/mL and for men are 2.0a 10.0ng/mL.
2.5. Statistical Analysis. Results are presented as mean and
standard deviations or median (range) for continuous
variables and as a number (%) for categorical variables. Data
Table 1: Demographic characteristics, anthropometric measures,
PRL levels, and inﬂammatory markers in patients with primary
antiphospholipid syndrome (pAPS) and controls.
pAPS Controls P
N = 55 N = 41
Age, years 42.03 ±11.63 37.37 ± 11.81 .053
Female gender, n (%) 47 (85.5) 35 (85.4) 1.00
Caucasianrace, n (%) 49 (89.1) 34 (82.9) .548
Disease duration,
months 93.13 ±61.96 — —
Weight, kg 74.54 ±19.99 63.45 ±8.68 .0009
Height, cm 155.53 ±33.32 154.09 ±34.94 .830
BMI, kg/cm2 29.2 ±7.32 28.9 ± 7.85 .0065
Waist, cm 90.63 ±16.74 81.83 ±8.14 .0022
PRL levels, ng/mL 8.94 ±7.02 8.71 ± 6.73 .876
HPRL, n (%) 5 (9.0) 5 (12.1) .740
CRP, mg/L 4.52 ±4.67 2.15 ± 2.60 .0063
ESR, mm/1st hour 13.81 ±13.33 5.92 ± 4.30 .0006
Data are presented as means ± standard deviations or percentages; t-tests
and chi-square tests were used.
were compared by t-tests or by the Mann-Whitney test for
continuous variables to evaluate diﬀerences among patients
with pAPS and controls and among pAPS patients with and
without HPRL. For categorical variables, diﬀerences were
assessed by a chi-square test or Fisher’s exact test. P values
less than .05 were considered signiﬁcant.
3.Results
Table 1 shows the demographic characteristics, anthropo-
metric measures, PRL levels, and inﬂammatory markers of
pAPS patients and controls. pAPS patients and controls were
similar in regards to mean age, female gender, and Caucasian
race. Patients had a mean disease duration of 93.13 ± 61.96
months.
pAPS patients had a higher weight (74.54 ± 19.99 versus
63.45±8.68kg,P = .0009)andBMI(29.2±7.32versus28.9±
7.85cm, P = .0065) compared to controls.
PRL levels were similar (Table 1) when comparing pAPS
patients and healthy controls (8.94 ± 7.02 versus 8.71 ±
6.73ng/mL, P = .876), as was the frequency of HPRL
(9.1 versus 12.1%, P = .740). No subject had any sign or
symptom relatedtoHPRL,such asgalactorrhea ormenstrual
disturbances.
Inﬂammatory parameters suchasCRP(4.52±4.67versus
2.15 ± 2.60mg/L, P = .0063) and ESR (13.81 ± 13.33 versus
5.92 ± 4.30mm/1st hour, P = .0006) were higher in pAPS
patients compared to controls (Table 1).
Comparison of the ﬁve hyperprolactinemic pAPS
patients to those with normoprolactinemia revealed no sig-
niﬁcant diﬀerences related to demographics (age, female sex,
and Caucasian race), anthropometrics (weight, height, and
BMI), antiphospholipid antibodies, inﬂammatory markers
(CRP and ESR), clinical manifestations (arterial, venous,Clinical and Developmental Immunology 3
Table 2: Comparison between primary antiphospholipid syndrome patients (pAPS) with hyperprolactin and normalPRL levels.
pAPS with HPRL pAPS with Normoprolactinemia P
N = 5 N = 50
Age (years) 34 42 .053
Female gender, n (%) 5 (100) 42 (84) 1.00
Caucasian race, n (%) 3 (60) 46 (92) .086
Disease duration, months 106 (27–189) 82 (1–224) .279
Weight, kg 70 (57–90) 75 (47–156) .237
Height, cm 161 (158–168) 162 (140–180) .215
BMI, kg/cm2 27 (22.3–31.9) 26.75 (27.5–42.2) .328
Waist, cm 81 (76–110) 91 (65–157) .294
Sedentarism, n (%) 5 (100) 29 (58) .144
Current smoking, n (%) 0 8 (16) 1.00
Previous smoking,n (%) 0 20 (40) .147
Arterial event, n (%) 3 (60) 34 (68) 1.00
Venous event, n (%) 2 (40) 28 (56) .649
Obstetric event, n (%) 1 (20) 21 (42) .638
Stroke, n (%) 2 (40) 22 (44) 1.00
Sneddon syndrome, n (%) 0 11 (22) .571
Limb ischemia, n (%) 2 (40) 6 (12) .149
Systemic arterial hypertension, n (%) 1 (20) 23 (46) .373
Acute Myocardial Infarction, n (%) 0 1 (2) 1.00
Angina, n (%) 0 7 (14) 1.00
Deep venous thrombosis, n (%) 2 (40) 23 (46) 1.00
Pulmonary thromboembolism, n (%) 1 (20) 9 (18) 1.00
Thrombocytopenia, n (%) 0 12 (24) .574
CRP, mg/L 0.87 (0.64–19) 3.22 (0.3–17.1) .494
ESR, mm/1st hour 8.1 (2–32) 9 (2–58) .287
Lupus anticoagulant, n (%) 3 (60) 34 (68) 1.00
Anticardiolipin IgM, n (%) 1 (20) 9 (18) 1.00
Anticardiolipin IgG, n (%) 2 (40) 18 (36) 1.00
Warfarin use, n (%) 4 (80) 46 (92) .391
Chloroquine use, n (%) 3 (60) 23 (46) .659
Statin use, n (%) 1 (20) 17 (34) 1.00
Acetylsalicylic acid use, n (%) 2 (40) 29 (58) .643
Dataarepresentedasmeans(rangeorpercentages);Mann-WhitneyandFischertestswereused.HPRLwasdeﬁnedasPRL > 10ng/mLformenand>15ng/mL
for women.
obstetric events, stroke, deep venous thrombosis, pul-
monary thromboembolism, angina, limb ischemia, myocar-
dial infarct, and thrombocytopenia), drug use (warfarin,
acetylsalicylic acid, chloroquine, and statin), current or
previous smoking, and diagnosis of systemic arterial hyper-
tension (P>. 05) (Table 2).
4.Discussion
This study demonstrated that pAPS patients presented
similar PRL levels compared to control (8.94 ± 7.02ng/mL
and 8.71 ± 6.73ng/mL, respectively). However, among the
patients (55) ﬁve (9.0%) showed hyperprolactinemia but an
equal number was also found among the control group (41).
Comparison between the hyperprolactinemic pAPS patients
with normoprolactinemic patients revealed no signiﬁcant
clinical diﬀerences.
PRL enhances immunoglobulin production [9], which
may contribute to increased autoreactivity. A variety of
autoantibodieswere observedinpatientswithHPRL,includ-
ing antibodies to PRL, endothelial cells, cardiolipin, β2
glycoproteinI (β2G P I ) ,R oa n dL a[ 10]. Praprotnik et al. [5]
observed that HPRL is not associated with increased throm-
bosis; however, HPRL was more common among patients
who had lupus anticoagulant activity as well as with some
of APS major manifestations such as obstetric complications
and did not relate to thrombosis. On the other hand, our
study did not ﬁnd any statistically signiﬁcant association4 Clinical and Developmental Immunology
between pAPS with HPRL and normoprolactinemia in
relation the presence of lupus anticoagulant, anticardiolipin
antibodies, and clinical manifestations as thrombotics ones.
According to other studies, PRL levels do not interfere
directly in the modulating plaquete function which suggests
that the prothrombotic eﬀect of this hormone may involve
other cells types [11]. It is worth to mention that our
population was possibly more homogenous (Table 1)t h a n
theoneused byPraprotnik and thatgeneticbackgroundmay
inﬂuence the results.
Obstetric eventsare associated with HPRL and antiphos-
pholipid antibodies [5, 12] with impaired endometrial dif-
ferentiation before conception. This mechanism contributes
to the high incidence of pregnancy complications in APS
[12]. Expression of decidual markers such as PRL, tissue
factor (TF), signal transducer, and activator of transcription
5 (Stat5), but not insulin-like growth factor-binding protein
1 (IGFBP-1), is signiﬁcantly lower in samples obtained from
aPL (+) patients when compared with aPL (−)g r o u p[ 12].
In other words, patients with recurrent pregnancy loss have
distinct endometrial gene expression proﬁles depending on
the presence or absence of circulating aPL antibodies. In our
study, only (1/5) patients with HPRL had obstetric event
(pregnancy loss in the ﬁrst trimester), and no signiﬁcant
correlation was found when pAPS were compared with
normoprolactinemia (P = .64). However, this ﬁnding may
beexplained bytherelatively small number ofpatientsin our
study.
Another interesting point of this study is that a wide
variety of APS clinical manifestations were analyzed, such
as neurological, haematological, cardiac, pulmonary, and
thrombotics ones, as well serological antibodies of this syn-
drome and anti-inﬂammmatory markers. In SLE patients,
PRL may have an eﬀect on autoantibody production. Thus,
autoimmune rheumatic disorders can be accompanied by
increased PRL levels. Previous studies have demonstrated
that lupus is associated with this endocrine alteration. The
prevalence of HPRL in patients with SLE in most of the
series ranges from 13 to 35% [13–15]. Moreover, one
study [16] evaluated whether antibodies to PRL play a
role in SLE patients with associated HPRL. They studied
259 consecutive SLE patients and suggested that anti-
PRL antibodies could be the cause of HPRL in a subset
of SLE patients, especially those with particularly high
serum PRL levels with a diagnosis of idiopathic HPRL.
The patients with anti-PRL antibody had fewer clinical
manifestations and less serological activity, indicating that
the biological activity of PRL was attenuated by the
autoantibody. A meta-analysis demonstrated a signiﬁcant
increase in PRL concentrations in SLE patients. PRL likely
stimulates lupus disease activity. Serum PRL and disease
activity have been positively associated, and abnormally
high PRL levels during pregnancy in SLE also correlate
with disease activity [17]. According to the aforementioned,
the best evidence for the association between PRL and
human disease exists for SLE [18]. Curiously, another study
which evaluated the prevalence and clinical signiﬁcance of
HPRL in APS concluded that HPRL was negatively related
to arthralgias, venous thrombosis, pulmonary microthrom-
bosis, pulmonary hypertension in APS, and neurological
manifestations in pAPS (P<. 05) [5]. However, our study
found no connection between clinical manifestations and
HPRL.
Certain limitations of our study must be addressed.
Serum PRL levels were only measured at a single time point
in our study and, thus, discrete alterations in the 24-hour
secretion patternofthehormonemayhavebeenmissed [19].
In addition, factors other than circadian rhythms, such as
age [20], menstrual cycle [21], sleep [22], and acute stressors
[23], could have inﬂuenced our results.
Finally, our study showed that HPRL does not seem
to play a role in clinical manifestations of the primary
antiphospholipid syndrome, making it diﬀerent from other
autoimmune rheumatic diseases as SLE.
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